Latest Breaking News On - Mount sinai professor of alzheimer disease research - Page 1 : comparemela.com

Vigil Neuroscience Announces Update on its Small Molecule TREM2 Agonist Program

- Announced VG-3927 as lead candidate to enter clinical development for potential treatment of Alzheimer’s Disease -

Marco colonnaMegan mcgrathSamuele gandyLeah gibsonExchange commissionMount sinai alzheimer disease research centerVigil neuroscience incDrug administrationCompany phaseWashington university school of medicineInvestor relations corporate communicationsMount sinai professor of alzheimer disease researchInvestigational new drugRobert rock belliveau professorWashington university schoolMount sinai professor

Vigil Neuroscience Announces Update on its Small Molecule TREM2 Agonist Program

- Announced VG-3927 as lead candidate to enter clinical development for potential treatment of Alzheimer’s Disease - - IND for VG-3927 now open; Phase 1 clinical trial in healthy volunteers allowed.

Samuele gandyMegan mcgrathMarco colonnaLeah gibsonWashington university school of medicineDrug administrationInvestor relations corporate communicationsMount sinai professor of alzheimer disease researchVigil neuroscience incCompany phaseExchange commissionMount sinai alzheimer disease research centerInvestigational new drugRobert rock belliveau professorWashington university schoolMount sinai professor

Vigil Neuroscience Announces Update on its Small Molecule TREM2 Agonist Program

Vigil Neuroscience Announces Update on its Small Molecule TREM2 Agonist Program
businessinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businessinsider.com Daily Mail and Mail on Sunday newspapers.

Samuele gandyLeah gibsonMarco colonnaMegan mcgrathDrug administrationMount sinai alzheimer disease research centerMount sinai professor of alzheimer disease researchInvestor relations corporate communicationsExchange commissionWashington university school of medicineVigil neuroscience incCompany phaseInvestigational new drugRobert rock belliveau professorWashington university schoolMount sinai professor